At the Fifth Asia Cell and Gene Therapy Innovation Summit 2024 held in Shanghai in early April, Shenzhen Cell Valley was honored with the Technological Breakthrough Award at the 2024 Asia Pacific Cell and Gene Therapy Innovation Star of the Year Award. The Pingshan-based company received recognition for its retroviral vector technology and its notable achievements in scientific research and clinical applications.

Gathering 2,539 companies from around the world, the summit and the awards showcased advancements in various domains, such as organoid cultivation, 3D cell culture, clinical scientific research, drug development, basic scientific research and others in cell and gene therapy. The event aimed to foster research and development (R&D) efforts while boosting the visibility and reputation of participating companies.

Shenzhen Cell Valley Biopharmaceuticals Co. Ltd. in Pingshan District. Photo from the company

Shenzhen Cell Valley Biopharmaceuticals Co. Ltd. serves as a comprehensive outsourcing service provider specializing in the cell and gene therapy industry. It stands out as the sole Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) with the capability for clinical-grade retroviral vector Good Manufacturing Practice (GMP) industrial production in China. The award underscores the company’s commitment to cutting-edge scientific research and sophisticated technologies.

Pingshan is actively building its “6+3” industrial clusters, including cell and gene. Over 70 companies in Pingshan are involved in cell and gene. Supported by a range of service platforms and research institutions, Pingshan is transitioning into a prominent cell and gene hub, complete with a comprehensive industrial chain encompassing R&D, and production processes.